Hikma Pharmaceuticals (LON:HIK) said it has made an “encouraging start” to 2026 and reiterated its full-year group guidance, citing performance across all three of its businesses and continued robust ...

Novo Nordisk (NVO) stock surged over 6% after FDA proposed removing weight-loss drugs from compounding list, hitting highest ...

My investment philosophy focuses on compounding capital at 12-15% annually, prioritizing high-quality, blue-chip companies with wide moats and strong balance sheets. I emphasize concentrated ...